Related Experiment Video
Updated: Aug 18, 2026
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
In-Vitro Generation of T-Cell Clones to Difluorophenylglyoxal: Implications for Understanding the Immunogenicity of
Paul Thomson1, Andrew Gibson1,2, Jackie Shang3
1Department Pharmacology and Therapeutics, University of Liverpool, LiverpoolL693GE, U.K.
Abstract:
MK-3207 was withdrawn from development because of drug-induced liver injury. Metabolic studies identified bioactivation to a protein-reactive 3,5-difluorophenylglyoxal (DFPG) intermediate. Although phenylglyoxal metabolites readily form protein adducts, their immunogenic potential has been poorly understood. We compared the immunogenicity of three DFPG isomers (3,5-, 2,4-, and 3,4-DFPG) using T-cell clones generated from treated healthy donor PBMCs. Reactive clones were detected against isomers with 3,5-DFPG inducing the strongest responses. Activation required antigen processing, and no cross-reactivity with MK-3207 was observed. These findings demonstrate the immunogenicity of 3,5-DFPG and show that structural differences among phenylglyoxal isomers influence T cell activation.
Insights
Drug-induced liver injury from MK-3207 was linked to a reactive intermediate, 3,5-difluorophenylglyoxal (DFPG). Studies show this DFPG isomer is immunogenic, activating T-cells and highlighting structural impacts on immune responses.
Area of Science:
- Drug metabolism and toxicology
- Immunology
- Medicinal chemistry
Background:
- Drug-induced liver injury (DILI) is a significant safety concern.
- Metabolism of MK-3207 leads to a reactive 3,5-difluorophenylglyoxal (DFPG) intermediate.
- The immunogenicity of phenylglyoxal metabolites is not well understood.
Purpose of the Study:
- To investigate the immunogenicity of different 3,5-difluorophenylglyoxal (DFPG) isomers.
- To understand the role of DFPG structure in T-cell activation.
- To explore the immune response related to MK-3207-induced liver injury.
Main Methods:
- Generation of T-cell clones from peripheral blood mononuclear cells (PBMCs) of healthy donors.
- Comparison of T-cell reactivity against three DFPG isomers (3,5-, 2,4-, and 3,4-DFPG).
- Assessment of antigen processing requirements for T-cell activation.
Main Results:
- Reactive T-cell clones were generated against DFPG isomers.
- The 3,5-DFPG isomer induced the strongest T-cell responses.
- T-cell activation was antigen processing-dependent and showed no cross-reactivity with the parent drug MK-3207.
Conclusions:
- 3,5-difluorophenylglyoxal (DFPG) is immunogenic.
- Structural variations in phenylglyoxal isomers significantly affect T-cell activation.
- These findings contribute to understanding DILI mechanisms and drug immunogenicity.
